Buscar

01/06/2024 CXCR4 Expression as a Prognostic Biomarker in Soft Tissue Sarcomas
Virgili, AC, Salazar, J, Gallardo, A, López-Pousa, A, Terés, R, Bagué, S, Orellana, R, Fumagalli, C, Mangues, R, Alba-Castellón, L, Unzueta, U, Casanova, I, Sebio, A. CXCR4 Expression as a Prognostic Biomarker in Soft Tissue Sarcomas. Diagnostics. 2024; 14(11)DOI:10.3390/diagnostics14111195. PMID:38893721. IF:3.300(Q1/2D).
01/06/2024 Immune phenotypes and histological growth patterns in resected lung metastasis of colorectal cancer patients to assess prognosis
Cullell, BM, Manrique, ACV, Piedra, A, Fumagalli, C, Mateo, FJP, Serda, PC, Mirallas, O, Martínez, E, Trujillo, JC, Belda-Sanchis, J, Szafranska, J, Paez, D. Immune phenotypes and histological growth patterns in resected lung metastasis of colorectal cancer patients to assess prognosis. ANNALS OF ONCOLOGY. 2024; 35DOI:10.1016/j.annonc.2024.05.133. PMID:. IF:65.400(Q1/1D).
01/04/2024 RET Fusion Testing in Patients With NSCLC: The RETING Study
Conde, E, Hernandez, S, Carrillo, JLR, Martinez, R, Alonso, M, Curto, D, Jimenez, B, Caminoa, A, Benito, A, Garrido, P, Clave, S, Arriola, E, Esteban-Rodriguez, I, De Castro, J, Sansano, I, Felip, E, Rojo, F, Dómine, M, Abdulkader, I, Garcia-Gonzalez, J, Teixido, C, Reguart, N, Compañ, D, Insa, A, Mancheño, N, Palanca, S, Juan-Vidal, O, Baixeras, N, Nadal, E, Cebollero, M, Calles, A, Martin, P, Salas, C, Provencio, M, Aranda, I, Massuti, B, Lopez-Vilaro, L, Majem, M, Paz-Ares, L, Lopez-Rios, F. RET Fusion Testing in Patients With NSCLC: The RETING Study. Jto Clinical And Research Reports. 2024; 5(4)DOI:10.1016/j.jtocrr.2024.100653. PMID:38525319. IF:(Q/D).
10/03/2024 Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG)
Gronchi, A, Palmerini, E, Quagliuolo, V, Broto, JM, Pousa, AL, Grignani, G, Brunello, A, Blay, JY, Tendero, O, Beveridge, RD, Ferraresi, V, Lugowska, I, Pizzamiglio, S, Verderio, P, Fontana, V, Donati, DM, Palassini, E, Sanfilippo, R, Bianchi, G, Bertuzzi, A, Morosi, C, Pasquali, S, Stacchiotti, S, Bagué, S, Coindre, JM, Miceli, R, Dei Tos, AP, Casali, PG. Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG). JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(8)DOI:10.1200/JCO.23.00908. PMID:38232337. IF:41.900(Q1/1D).
01/03/2024 Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant Therapy
Arqueros, C, Gallardo, A, Vidal, S, Osuna-Gómez, R, Tibau, A, Bell, OL, Cajal, T, Lerma, E, Lobato-Delgado, B, Salazar, J, Barnadas, A. Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant Therapy. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2024; 25(5)DOI:10.3390/ijms25052627. PMID:38473874. IF:4.900(Q1/3D).
01/03/2024 A Clinicopathologic and Immunohistochemical Analysis of 46 Uterine Mesenchymal Tumors Including Conventional Adenosarcomas, Atypical Uterine Polyps and Other Related Sarcomas
Angelo, ED, Espinosa, I, Wang, AH, Kingsley, L, Nasr, S, Zdravkovic, S, Howitt, B, Prat, J. A Clinicopathologic and Immunohistochemical Analysis of 46 Uterine Mesenchymal Tumors Including Conventional Adenosarcomas, Atypical Uterine Polyps and Other Related Sarcomas. LABORATORY INVESTIGATION. 2024; 104(3)DOI:. PMID:. IF:4.200(Q1/1D).
01/03/2024 Loss of Expression of ARID1a and PBRM1 Proteins Is Associated with Poor Prognosis in Mullerian Adenosarcomas
Espinosa, I, D'Angelo, E, Gallardo, A, Lee, CH, Koebel, M, Prat, J. Loss of Expression of ARID1a and PBRM1 Proteins Is Associated with Poor Prognosis in Mullerian Adenosarcomas. LABORATORY INVESTIGATION. 2024; 104(3)DOI:. PMID:. IF:4.200(Q1/1D).
01/03/2024 Tumor Microenvironment in Dedifferentiated and Undifferentiated Endometrial Carcinomas: The Emerging Role of Spatial Cancer-Immunophenotypes and HLA Class I Expression
De Leo, A, Ceccarelli, C, Grillini, M, de Biase, D, Tallini, G, Espinosa, I, Koebel, M, Lee, CH. Tumor Microenvironment in Dedifferentiated and Undifferentiated Endometrial Carcinomas: The Emerging Role of Spatial Cancer-Immunophenotypes and HLA Class I Expression. LABORATORY INVESTIGATION. 2024; 104(3)DOI:. PMID:. IF:4.200(Q1/1D).
10/08/2023 Probing the Biosafety of Implantable Artificial Secretory Granules for the Sustained Release of Bioactive Proteins
Álamo P., Parladé E., Favaro, MTP, Gallardo A., Mendoza R., Ferreira, LCS, Roher N., Mangues R., Villaverde A., Vázquez E.. Probing the Biosafety of Implantable Artificial Secretory Granules for the Sustained Release of Bioactive Proteins. ACS Applied Materials & Interfaces. 2023; 15(33)DOI:10.1021/acsami.3c08643. PMID:37614001. IF:8.500(Q1/2D).
01/07/2023 Prevalence and clinical impact of alcohol withdrawal syndrome in alcohol-associated hepatitis and the potential role of prophylaxis: a multinational, retrospective cohort study
Marti-Aguado, D, Gougol, A, Gomez-Medina, C, Jamali, A, Abo-Zed, A, Morales-Arraez, D, Jimenez-Sosa, A, Burns, K, Bawa, A, Hernandez, A, Pujol, C, Alvarado-Tapias, E, Szafranska, J, Chiu, WK, Villagrasa, A, Ventura-Cots, M, Gandicheruvu, H, Lluch, P, Chen, HW, Rachakonda, V, Duarte-Rojo, A, Bataller, R. Prevalence and clinical impact of alcohol withdrawal syndrome in alcohol-associated hepatitis and the potential role of prophylaxis: a multinational, retrospective cohort study. Eclinicalmedicine. 2023; 61DOI:10.1016/j.eclinm.2023.102046. PMID:37415844. IF:9.600(Q1/1D).
28/06/2023 Sarcomatoid transformation of a basal cell carcinoma following treatment with hedgehog inhibitors
Barrabes-Torrella, C, Arandes-Marcocci, J, Armillas-Lliteras, L, Posada-Caez, RA, Koptseva, I, Fumagalli, C, Pinol-Ballus, D, Salleras-Redonnet, M. Sarcomatoid transformation of a basal cell carcinoma following treatment with hedgehog inhibitors. BRITISH JOURNAL OF DERMATOLOGY. 2023; 189(4)DOI:10.1093/bjd/ljad206. PMID:37378960. IF:11.000(Q1/1D).
01/06/2023 Extranodal natural killer/T-cell lymphoma nasal type in a western population: Molecular profiling identifies new therapeutic targets
Barca, EG, Tomas-Roca, L, Esteve, A, Rodriguez, M, Gato, L, Alonso-Alonso, R, Garcia-Sancho, AM, Cordoba, R, Monter-Rovira, A, Bastos-Oreiro, M, Burgues, JMB, Sayas, MJ, Alegria, MCV, Sanchez-Blanco, JJ, Pellicer, MR, Henriquez, HDL, de Ona, R, Cabezudo, ME, Infante, MS, Hernandez, JAQ, Sanz-Pamplona, R, Blanco, O, Mozos, A, Climent, F, Piris, MA. Extranodal natural killer/T-cell lymphoma nasal type in a western population: Molecular profiling identifies new therapeutic targets. AMERICAN JOURNAL OF HEMATOLOGY. 2023; 98(6)DOI:10.1002/ajh.26904. PMID:36882876. IF:10.100(Q1/1D).
11/05/2023 The Phosphorylation of Kv1.3: A Modulatory Mechanism for a Multifunctional Ion Channel
Navarro-Perez, M, Estadella, I, Benavente-Garcia, A, Orellana-Fernandez, R, Petit, A, Ferreres, JC, Felipe, A. The Phosphorylation of Kv1.3: A Modulatory Mechanism for a Multifunctional Ion Channel. Cancers. 2023; 15(10)DOI:10.3390/cancers15102716. PMID:37345053. IF:4.500(Q1/3D).
01/05/2023 Malignant rhabdoid tumors of the vulva versus epithelioid sarcomas: a clinicopathologic, immunohistochemical, and molecular genetics study
Espinosa, I, D'Angelo, E, De Brot, L, Prat, J. Malignant rhabdoid tumors of the vulva versus epithelioid sarcomas: a clinicopathologic, immunohistochemical, and molecular genetics study. HUMAN PATHOLOGY. 2023; 135DOI:10.1016/j.humpath.2023.02.006. PMID:36863690. IF:2.700(Q2/4D).
01/05/2023 Macrophage CD5L is a target for cancer immunotherapy
Sanchez-Moral, L, Paul, T, Martori, C, Font-Diaz, J, Sanjurjo, L, Aran, G, Tellez, E, Blanco, J, Carrillo, J, Ito, M, Tuttolomondo, M, Ditzel, HJ, Fumagalli, C, Tapia, G, Sidorova, J, Masnou, H, Fernandez-Sanmartin, MA, Lozano, JJ, Vilaplana, C, Rodriguez-Cortes, A, Armengol, C, Valledor, AF, Kremer, L, Sarriasa, MR. Macrophage CD5L is a target for cancer immunotherapy. EBioMedicine. 2023; 91DOI:10.1016/j.ebiom.2023.104555. PMID:37054630. IF:9.700(Q1/1D).
01/04/2023 Placental site trophoblastic tumor (PSTT): a case report and review of the literature
Zampacorta, C, Pasciuto, MP, Ferro, B, Lucidi, A, Maestro, AS, Espinosa, I, D'Angelo, E, Prat, J. Placental site trophoblastic tumor (PSTT): a case report and review of the literature. Pathologica. 2023; 115(2)DOI:10.32074/1591-951X-873. PMID:37114629. IF:(Q/D).
01/01/2023 CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 study
Frezza A.M., Stacchiotti S., Chibon F., Coindre, JM, Italiano A., Romagnosa C., Bagué S., Dei Tos A.P., Braglia L., Palmerini E., Quagliuolo V., Broto J.M., Pousa, AL, Grignani G., Brunello A., Blay, JY, Beveridge R.D., Lugowska I., Lesluyes T., Maestro R., Merlo F.D., Casali P.G., Gronchi A.. CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 study. Cancer Medicine. 2023; 12(2)DOI:10.1002/cam4.5015. PMID:35848358. IF:2.900(Q2/5D).
01/01/2023 Potent Anticancer Activity of CXCR4-Targeted Nanostructured Toxins in Aggressive Endometrial Cancer Models
Medina-Gutiérrez E., García-León A., Gallardo A., Álamo P., Alba-Castellón L., Unzueta U., Villaverde A., Vázquez E., Casanova I., Mangues R.. Potent Anticancer Activity of CXCR4-Targeted Nanostructured Toxins in Aggressive Endometrial Cancer Models. Cancers. 2023; 15(1)DOI:10.3390/cancers15010085. PMID:36612081. IF:4.500(Q1/3D).
01/01/2023 Validation of a Pathological Score for the Assessment of Bronchial Biopsies in Severe Uncontrolled Asthma: Beyond Blood Eosinophils
Cosio B.G., Shafiek H., Iglesias A., Mosteiro M., Gonzalez-Piñeiro A., Rodríguez M., García-Cosío M., Busto E., Martin J., Mejías L., Benito A., López Vilaro L., Gómez C.. Validation of a Pathological Score for the Assessment of Bronchial Biopsies in Severe Uncontrolled Asthma: Beyond Blood Eosinophils. ARCHIVOS DE BRONCONEUMOLOGIA. 2023; 59(8)DOI:10.1016/j.arbres.2023.05.014. PMID:37414638. IF:8.700(Q1/1D).
01/01/2023 Alterations in p53, Microsatellite Stability and Lack of MUC5AC Expression as Molecular Features of Colorectal Carcinoma Associated with Inflammatory Bowel Disease
Gené M., Cuatrecasas M., Amat I., Veiga J.A., Fernández Aceñero M.J., Fusté Chimisana V., Tarragona J., Jurado I., Fernández-Victoria R., Martínez Ciarpaglini C., Alenda González C., Zac C., Ortega de la Obra P., Fernández-Figueras M.T., Esteller M., Musulen E.. Alterations in p53, Microsatellite Stability and Lack of MUC5AC Expression as Molecular Features of Colorectal Carcinoma Associated with Inflammatory Bowel Disease. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2023; 24(10)DOI:10.3390/ijms24108655. PMID:37240002. IF:4.900(Q1/3D).